1100070 北京首都医科大学附属北京天坛医院神经病学中心
2国家神经系统疾病临床医学研究中心
3北京脑重大疾病研究院脑卒中研究所
4脑血管病转化医学北京市重点实验室
5北京中医药大学东方医院
6首都医科大学人脑保护高精尖创新中心
7The University of Tennessee Health Science Center,Tennessee,USA
WANG Yong-Jun, LI Zi-Xiao, SUO Yue, ZHOU Hong-Yu, ZHANG Qi-Hui,HAN Chong, LI Shi-Yu, DING Ya-Rong, WANG Yu, DAI Li-Ye, WANG Xue-Chun, CHENG Ai-Chun, FENG Zhi-Yuan,ZHANG Chen, ZHANG Xing. Review of Stroke Studies in 2019[J]. Chinese Journal of Stroke, 2020, 15(01): 1-17.
[1] GBD 2016 Stroke Collaborators. Global,regional,and national burden of stroke,1990-2016:asystematic analysis for the global burden of diseasestudy 2016[J]. Lancet Neurol,2019,18(5):439-458.[2] ZHOU M,WANG H,ZENG X,et al. Mortality,morbidity,and risk factors in China and its provinces,1990-2017:a systematic analysis for the GlobalBurden of Disease Study 2017[J]. Lancet,2019,394(10204):1145-1158.[3] The National Institute of Neurological Disordersand Stroke rt-PA Stroke Study Group. Tissueplasminogen activator for acute ischemic stroke[J].N Engl J Med,1995,333(24):1581-1587.[4] HACKE W,KASTE M,BLUHMKI E,et al.Thrombolysis with alteplase 3 to 4.5 hours afteracute ischemic stroke[J]. N Engl J Med,2008,359(13):1317-1329.[5] MA H,CAMPBELL B C V,PARSONS M W,etal. Thrombolysis guided by perfusion imaging up to9 hours after onset of stroke[J]. N Engl J Med,2019,380(19):1795-1803.[6] CAMPBELL B C V,MA H,RINGLEB P A,etal. Extending thrombolysis to 4.5-9 h and wake-upstroke using perfusion imaging:a systematic review了新思路[44-45]。卒中后肢体功能障碍为家庭和社会带来了巨大负担,期待有更多的研究寻找更有效的康复方式。回眸2019,科技的力量推动着脑血管病研究的步伐不断向前。2019年,世界科技界的进展也令人瞩目,2月份首张黑洞照片公布;年中,首张量子纠缠照片公布,科学家在宏观和微观领域都在不断地进行探索。谷歌的量子计算机实现“量子霸权”;清华大学异构融合类脑计算芯片登上Nature 杂志的封面;马斯克宣布“脑机接口”装置的突破……各领域新技术的发展,似乎在提示我们,2020年后真的是“未来已至”吗?未来的技术会在多大程度上促进医学探索,又会在多大程度上误导医学的发展?2020年,跨入未来,对于卒中领域的学者,需要学习利用科技,引领科技在正确的道路上推动脑血管病研究和临床实践的发展。and meta-analysis of individual patient data[J].Lancet,2019,394(10193):139-147.[7] DAVIS S M,DONNAN G A,PARSONS M W,etal. Effects of alteplase beyond 3 h after stroke inthe echoplanar imaging thrombolytic evaluationtrial(EPITHET):a placebo-controlled randomisedtrial[J]. Lancet Neurol,2008,7(4):299-309.[8] AMIRI H,BLUHMKI E,BENDSZUS M,etal. European Cooperative Acute Stroke Study-4:extending the time for thrombolysis in emergencyneurological deficits ECASS-4:ExTEND[J]. Int JStroke,2016,11(2):260-267.[9] TURK A S 3rd,SIDDIQUI A,FIFI J T,et al.Aspiration thrombectomy versus stent retrieverthrombectomy as first-line approach for large vesselocclusion(COMPASS):a multicentre,randomised,open label,blinded outcome,non-inferiority trial[J].Lancet,2019,393(10175):998-1008.[10] YOO A J,KHATRI P,MOCCO J,et al. Impact ofthrombus length on outcomes after intra-arterialaspiration thrombectomy in the THERAPY trial[J].Stroke,2017,48(7):1895-1900.[11] LAPERGUE B,BLANC R,GORY B,et al. Effectof endovascular contact aspiration vs stent retrieveron revascularization in patients with acute ischemicstroke and large vessel occlusion:the ASTERrandomized clinical trial[J]. JAMA,2017,318(5):443-452.[12] NOGUEIRA R G,FREI D,KIRMANI J F,et al.Safety and efficacy of a 3-Dimensional stent retrieverwith aspiration-based thrombectomy vs aspirationbasedthrombectomy alone in acute ischemic strokeintervention:a randomized clinical trial[J]. JAMANeurol,2018,75(3):304-311.[13] HART R G,DIENER H C,COUTTS S B,et al.Embolic strokes of undetermined source:the case fora new clinical construct[J]. Lancet Neurol,2014,13(4):429-438.[14] HARLOFF A,SCHLACHETZKI F. Rivaroxabanfor stroke prevention after embolic stroke ofundetermined source[J]. N Engl J Med,2018,379(10):986-987.[15] DIENER H C,SACCO R L,EASTON J D,et al.Dabigatran for prevention of stroke after embolicstroke of undetermined source[J]. NEJM,2019,380(20):1906-1917.[16] PACIARONI M,KAMEL H. Do the results of RESPECTESUS call for a revision of the embolicstroke of undetermined source definition?[J]. Stroke,2019,50(4):1032-1033.[17] HEALEY J S,GLADSTONE D J,SWAMINATHAN B,et al. Recurrent stroke withrivaroxaban compared with aspirin according topredictors of atrial fibrillation:secondary analysis ofthe NAVIGATE ESUS randomized clinical trial[J].JAMA neurol,2019,76(7):764-773.[18] NTAIOS G,SWAMINATHAN B,BERKOWITZS D,et al. Efficacy and safety of rivaroxaban versusaspirin in embolic stroke of undetermined sourceand carotid atherosclerosis[J]. Stroke,2019,50(9):2477-2485.[19] AMARENCO P,GOLDSTEIN L B,SZAREKM,et al. Effects of intense low-density lipoproteincholesterol reduction in patients with stroke ortransient ischemic attack:the Stroke Preventionby Aggressive Reduction in Cholesterol Levels(SPARCL)trial[J]. Stroke,2007,38(12):3198-3204.[20] AMARENCO P,KIM J S,LABREUCHE J,et al.A comparison of two LDL cholesterol targets afterischemic stroke[J]. N Engl J Med,2020,382(1):9.[21] KRISHNAMURTHI R V,FEIGIN V L,FOROUZANFAR M H,et al. Global and regionalburden of first-ever ischaemic and haemorrhagicstroke during 1990-2010:findings from the GlobalBurden of Disease Study 2010[J/OL]. LancetGlob Health,2013,1(5):e259-e281. https://doi.org/10.1016/S2214-109X(13)70089-5.[22] KEEP R F,HUA Y,XI G. Intracerebralhaemorrhage:mechanisms of injury and therapeutictargets[J]. Lancet Neurol,2012,11(8):720-731.[23] HANLEY D F,THOMPSON R E,ROSENBLUMM,et al. Efficacy and safety of minimally invasivesurgery with thrombolysis in intracerebralhaemorrhage evacuation(MISTIE Ⅲ):arandomised,controlled,open-label,blindedendpoint phase 3 trial[J]. Lancet,2019,393(10175):1021-1032.[24] KURAMATSU J B,BIFFI A,GERNER S T,etal. Association of surgical hematoma evacuation vsconservative treatment with functional outcome inpatients with cerebellar intracerebral hemorrhage[J].JAMA,2019,322(14):1392-1403.[25] PETERS S A,HUXLEY R R,WOODWARDM. Diabetes as a risk factor for stroke in womencompared with men:a systematic review andmeta-analysis of 64 cohorts,including 775,385individuals and 12,539 strokes[J]. Lancet,2014,383(9933):1973-1980.[26] YONG M,KASTE M. Dynamic of hyperglycemiaas a predictor of stroke outcome in the ECASS-Ⅱtrial[J]. Stroke,2008,39(10):2749-2755.[27] BRUNO A,KENT T A,COULL B M,et al.Treatment of hyperglycemia in ischemic stroke(THIS):a randomized pilot trial[J]. Stroke,2008,39(2):384-389.[28] GRAY C S,HILDRETH A J,SANDERCOCK PA,et al. Glucose-potassium-insulin infusions in themanagement of post-stroke hyperglycaemia:theUK Glucose Insulin in Stroke Trial(GIST-UK)[J].Lancet Neurol,2007,6(5):397-406.[29] POWERS W J,RABINSTEIN A A,ACKERSONT,et al. Guidelines for the early management ofpatients with acute ischemic stroke:2019 updateto the 2018 guidelines for the early management ofacute ischemic stroke:a guideline for healthcareprofessionals from the American Heart Association/American Stroke Association[J/OL]. Stroke,2019,50(12):e344-e418. https://doi.org/10.1161/STR.0000000000000211.[30] 中华医学会神经病学分会. 中国急性缺血性脑卒中诊治指南2018[J]. 中华神经科杂志,2018,51(9):666-682.[31] JOHNSTON K C,BRUNO A,PAULS Q,et al.Intensive vs standard treatment of hyperglycemiaand functional outcome in patients with acuteischemic stroke:the SHINE randomized clinicaltrial[J]. JAMA,2019,322(4):326-335.[32] The SPRINT MIND Investigators for the SPRINTResearch Group,WILLIAMSON J D,PAJEWSKIN M,et al. Effect of intensive vs standard bloodpressure control on probable dementia:a randomizedclinical trial[J]. JAMA,2019,321(6):553-561.[33] YAFFE K. Prevention of cognitive impairment withintensive systolic blood pressure control[J]. JAMA,2019,321(6):548-549.[34] HACHINSKI V,EINHAUPL K,GANTEN D,et al.Preventing dementia by preventing stroke:the BerlinManifesto[J]. Alzheimers Dement,2019,15(7):961-984.[35] SABIA S,FAYOSSE A,DUMURGIER J,et al.Association of ideal cardiovascular health at age 50with incidence of dementia:25 year follow-up ofWhitehall Ⅱ cohort study[J/OL]. BMJ,2019,366:l4414. https://doi.org/10.1136/bmj.l4414.[36] The SPRINT MIND Investigators for the SPRINTResearch Group,NASRALLAH I M,PAJEWSKIN M,et al. Association of intensive vs standardblood pressure control with cerebral white matterlesions[J]. JAMA,2019,322(6):524-534.[37] The ENOS Trial Investigators. Efficacy of nitricoxide,with or without continuing antihypertensivetreatment,for management of high blood pressure in acute stroke(ENOS):a partial-factorial randomisedcontrolled trial[J]. Lancet,2015,385(9968):617-628.[38] The RIGHT-2 Investigators. Prehospital transdermalglyceryl trinitrate in patients with ultra-acutepresumed stroke(RIGHT-2):an ambulance-based,randomised,sham-controlled,blinded,phase 3trial[J]. Lancet,2019,393(10175):1009-1020.[39] RODGERS H,BOSOMWORTH H,KREBS HI,et al. Robot assisted training for the upper limbafter stroke(RATULS):a multicentre randomisedcontrolled trial[J]. Lancet,2019,394(10192):51-62.[40] STINEAR C M,BYBLOW W D,ACKERLEY SJ,et al. PREP2:a biomarker-based algorithm forpredicting upper limb function after stroke[J]. AnnClin Transl Neurol,2017,4(11):811-820.[41] CRAMER S C,WOLF S L,ADAMS H P,et al.Stroke recovery and rehabilitation research:issues,opportunities,and the National Institutes of HealthStrokeNet[J]. Stroke,2017,48(3):813-819.[42] LOHSE K R,LANG C E,BOYD L A. Is morebetter? Using metadata to explore dose-responserelationships in stroke rehabilitation[J]. Stroke,2014,45(7):2053-2058.[43] MEHRHOLZ J,POHL M,PLATZ T,et al.Electromechanical and robot-assisted arm trainingfor improving activities of daily living,armfunction,and arm muscle strength after stroke[J/OL].Cochrane Database Sys t Rev,2018,9:Cd006876.https://doi.org/10.1002/14651858.CD006876.pub5.[44] BERNHARDT J,HAYWARD K S,KWAKKELG,et al. Agreed definitions and a shared vision fornew standards in stroke recovery research:TheStroke Recovery And Rehabilitation RoundtableTaskforce[J]. Int J Stroke,2017,12(5):444-450.[45] BERNHARDT J,MEHRHOLZ J. Robotic-assistedtraining after stroke:RATULS advances science[J].Lancet,2019,394(10192):6-8.